Our objective was to investigate the association of CYP2D6
symptoms and side-effects of patients with schizophrenia.
The subjects were 156 patients with schizophrenia undergoing antipsychotic treatment
at a psychiatric clinic. Patients with co-morbid diagnoses of substance abuse or mental retardation were
excluded from the study. Psychopathology was evaluated using the Positive and Negative Symptoms
Scale (PANSS). Extrapyramidal side-effects and akathisia were assessed with the Simpson Angus Scale
(SAS) and the Barnes Akathisia Rating Scale (BARS), respectively. DNA was extracted from blood and
subjected to PCR-genotyping.
We found that CYP2D6
polymorphisms were significantly associated with a subtotal
negative PANSS score. In addition, CYP2D6
is not related to side-effects of antipsychotic therapy, or
SAS and BARS scores. The results suggest that CYP2D6
polymorphisms may have implications in
may be a predictor for treatment outcomes of patients with
schizophrenia. However, further investigation is required to confirm these findings in a larger sample.